A National Cheng Kung University (NCKU) research team has discovered
Near-Infrared Light-Responsive oligonucleotide-gated Au nanoensembles
(Au nanorod complex), a potent new anti-cancer complex that is seen as a
promising targeted therapy for curing cancer.
This medical discovery was selected as an important and urgent paper,
becoming the image of back cover in the July 2012 issue of Advanced
Materials, and has drawn big attention in the academic world and the
biotechnology industry as well.
The team, led by Chen-Sheng Yeh, NCKU distinguished professor of
Department of Chemistry, focused on the development of NIR
light-responsive oligonucleotide-gated Au nanoensembles (Au nanorod
complex) for cancer therapy and the result proved that Au nanorod
complex could provide better efficiency of cancer therapy by reducing
the cancer survival rates by 30%.
Au nanorod complex provides a new platform for cancer therapy, a
platform which, depending on different diseases, encapsulates different
drugs and small interfering RNA (siRNA) which has special functions to
achieve chemotherapy and gene therapy, according to Professor Yeh.
Professor Yeh pointed out that the surface of Au nanorod complex coated
with silica can encapsulate anti-cancer drugs.
To avoid the loss of anti-cancer drugs from Au nanorod complex during
the delivery process and reduce side effects of anti-cancer drugs, the
double-stranded DNA (dsDNA) as a net in covering the surface pores was
used to conjugate on the surface pores of silica.
Experimental results show that cancer survival rate can be reduced from
80% to about 50%, confirming the gold nanorods pharmaceutical compound
has achieved good therapeutic effect.
The advantage of using NIR light to trigger drug release was that NIR
was the biological window, where both blood and soft tissues
transmission is optimal due to low energy absorption, providing maximum
penetration. Therefore, the developed Au nanorod complex has triggered
drug release, maximizing the therapeutic properties of both chemotherapy
and gene therapy.
Moreover, the design of the treatment which can be tailored by the
medical needs to load the appropriate drug treatment is believed to be a
very curative treatment platform, according to Yeh.
Yeh's team has applied for patent in Taiwan and the United States, and
will continue to conduct animal testing and human trials.